Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (REGN – Research Report), DocGo (DCGO – Research Report) and Revvity (RVTY – Research Report).
Regeneron (REGN)
Goldman Sachs analyst Salveen Richter initiated coverage with a Buy rating on Regeneron on April 25 and set a price target of $1126.00. The company’s shares closed last Monday at $892.48.
According to TipRanks.com, Richter is a 5-star analyst with an average return of
Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $1048.63, which is a 18.7% upside from current levels. In a report issued on April 10, Leerink Partners also maintained a Buy rating on the stock.
See Insiders’ Hot Stocks on TipRanks >>
DocGo (DCGO)
Stifel Nicolaus analyst David Grossman maintained a Buy rating on DocGo today and set a price target of $6.50. The company’s shares closed last Monday at $3.62, close to its 52-week low of $2.78.
According to TipRanks.com, Grossman is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for DocGo with a $9.92 average price target.
Revvity (RVTY)
In a report released today, Daniel Arias from Stifel Nicolaus maintained a Hold rating on Revvity, with a price target of $110.00. The company’s shares closed last Monday at $105.02.
According to TipRanks.com, Arias is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Revvity with a $117.22 average price target, a 13.3% upside from current levels. In a report released today, Barclays also maintained a Hold rating on the stock with a $116.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REGN:
- Regeneron announces presentations on EYLEA HD, EYLEA Injection at ARVO meeting
- EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
- Regeneron price target raised to $1,175 from $1,125 at Oppenheimer
- Regeneron, Mammoth collaborate to purse next-generation gene editing
- Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
